Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Trainings > Ombea - Yes / No? > Flashcards

Ombea - Yes / No? Flashcards

1
Q

Branded PV/MF

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment Considerations in Polycythemia Vera and Myelofibrosis: A Real-World Patient Case Discussion

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Branded PV

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Intervening with Jakafi® (ruxolitinib) to Achieve Durable Count Control: Real-World Patient Case Discussion

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Branded MF

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis | A Real World Patient Case Discussion

A

Yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

GVHD

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Consider Jakafi ® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PEMAZYRE

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The First and Only Treatment for Locally Advanced or Metastatic Cholangiocarcinoma

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MONJUVI

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Monjuvi (tafasitamab-cxix) for Use as Second-Line Therapy in Adult Patients with R/R DLBCL, in Combination with Lenalidomide

A

No

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Virtual Abridged Branded PV

A

No - Zoom Polling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Intervening With Jakafi® (ruxolitinib) to Achieve Durable Count Control—Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

A

No - Zoom Polling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Virtual Abridged Branded MF

A

No - Zoom Polling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Intervening With Jakafi® (ruxolitinib) at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis

A

No - Zoom Polling

17
Q

Virtual Abridged GVHD

A

No

18
Q

Consider Jakafi ® (ruxolitinib) At the First Sign of Steroid-Refractory Acute GVHD

A

No

19
Q

Inst. Branded MF

A

Yes

20
Q

Intervening With Ruxolitinib at Diagnosis in Patients With Intermediate- or High-Risk Myelofibrosis - Real-World Patient Case Discussion

A

Yes

21
Q

Inst. Branded PV

A

Yes

22
Q

Intervening With Ruxolitinib to Achieve Durable Count Control: Real-World Patient Case Discussion - Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea

A

Yes

23
Q

Journal Article Review: COMFORT 5 year

A

No

24
Q

AN IN-DEPTH REVIEW:

Long-Term Findings From COMFORT-II, a Phase 3 Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis

A

No

25
Q

Journal Article Review: Response 1

A

No

26
Q

AN IN-DEPTH REVIEW:

Ruxolitinib Versus Standard Therapy for the Treatment of Polycythemia Vera

A

No

27
Q

Journal Article Review: Response 2

A

No

28
Q

AN IN-DEPTH REVIEW:
Ruxolitinib for the treatment of
inadequately controlled polycythemia
vera without splenomegaly

A

No

29
Q

Journal Article Review: REACH2

A

No

30
Q

Consider Jakafi® (ruxolitinib)
At the First Sign of Steroid-Refractory
Acute GVHD
In adult and pediatric patients 12 years and older

A

No

31
Q

Journal Article Review: RESPONSE 5

A

No

32
Q 
AN IN-DEPTH REVIEW:
Long-Term Efficacy and Safety of
Ruxolitinib Versus Best Available Therapy
in Polycythaemia Vera (RESPONSE):
5-Year Follow Up of a Phase 3 Study
A

No

33
Q

Inst. Unbranded PV

A

Yes

34
Q

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion

A

Yes

35
Q

Unbranded PV

A

Yes

36
Q

Identifying Patients With Clinical Characteristics of Advanced Polycythemia Vera— Real-World Patient Case Discussion

A

Yes

37
Q

Virtual Abridged Unbranded PV

A

No – Zoom Polling

38
Q

Identifying the Clinical Characteristics of Advanced Polycythemia Vera

A

No – Zoom Polling

Trainings (5 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions